Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2000 May;55(5):355–358. doi: 10.1136/thorax.55.5.355

Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs

J Elborn 1, R Prescott 1, B Stack 1, M Goodchild 1, J Bates 1, C Pantin 1, N Ali 1, D Shale 1, M Crane 1
PMCID: PMC1745744  PMID: 10770814

Abstract

BACKGROUND—A previous retrospective study suggested that a policy of regular anti-pseudomonal antibiotic treatment improved pulmonary function and increased survival in patients with cystic fibrosis chronically infected with Pseudomonas species. The results of a prospective multicentre study to compare the effects on pulmonary function and mortality of three monthly elective anti-pseudomonal antibiotic treatment with conventional symptomatic treatment are reported.
METHODS—Sixty patients with cystic fibrosis, chronically infected with P aeruginosa, were randomised to the two treatment arms (elective or symptomatic) and followed clinically at yearly reviews. The major end points were changes in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). Survival was a secondary end point.
RESULTS—Patients in the symptomatic group received a mean of three antibiotic treatments each year and those in the elective group received four antibiotic treatments during each year of the study. No significant differences in FEV1 and FVC were found between the two groups after three years. There was a statistically non-significant higher rate of deaths in the elective group (n = 4), three of which were associated with B cepacia infection, compared with the symptomatic group (n =0).
CONCLUSIONS—This study did not demonstrate an advantage of a policy of elective antibiotic treatment over symptomatic treatment in patients with cystic fibrosis chronically infected with Pseudomonas species.



Full Text

The Full Text of this article is available as a PDF (130.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cheng K., Smyth R. L., Govan J. R., Doherty C., Winstanley C., Denning N., Heaf D. P., van Saene H., Hart C. A. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996 Sep 7;348(9028):639–642. doi: 10.1016/S0140-6736(96)05169-0. [DOI] [PubMed] [Google Scholar]
  2. Chrispin A. R., Norman A. P. The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol. 1974;2(2):101–105. doi: 10.1007/BF01314939. [DOI] [PubMed] [Google Scholar]
  3. Cystic fibrosis in the United Kingdom 1977-85: an improving picture. British Paediatric Association Working Party on Cystic Fibrosis. BMJ. 1988 Dec 17;297(6663):1599–1602. doi: 10.1136/bmj.297.6663.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. David T. J. Cystic fibrosis. Arch Dis Child. 1990 Jan;65(1):152–157. doi: 10.1136/adc.65.1.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Denton M., Wilcox M. H. Antimicrobial treatment of pulmonary colonization and infection by pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother. 1997 Oct;40(4):468–474. doi: 10.1093/jac/40.4.468. [DOI] [PubMed] [Google Scholar]
  6. Elborn J. S., Bell S. C. Nutrition and survival in cystic fibrosis. Thorax. 1996 Oct;51(10):971–972. doi: 10.1136/thx.51.10.971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Elborn J. S., Shale D. J., Britton J. R. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax. 1991 Dec;46(12):881–885. doi: 10.1136/thx.46.12.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. FitzSimmons S. C. The changing epidemiology of cystic fibrosis. J Pediatr. 1993 Jan;122(1):1–9. doi: 10.1016/s0022-3476(05)83478-x. [DOI] [PubMed] [Google Scholar]
  9. Frederiksen B., Koch C., Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997 May;23(5):330–335. doi: 10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  10. Høiby N., Koch C. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax. 1990 Nov;45(11):881–884. doi: 10.1136/thx.45.11.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nir M., Lanng S., Johansen H. K., Koch C. Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre. Thorax. 1996 Oct;51(10):1023–1027. doi: 10.1136/thx.51.10.1023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Norman D., Elborn J. S., Cordon S. M., Rayner R. J., Wiseman M. S., Hiller E. J., Shale D. J. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax. 1991 Feb;46(2):91–95. doi: 10.1136/thx.46.2.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pedersen S. S., Koch C., Høiby N., Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother. 1986 Apr;17(4):505–516. doi: 10.1093/jac/17.4.505. [DOI] [PubMed] [Google Scholar]
  14. Ramsey B. W. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996 Jul 18;335(3):179–188. doi: 10.1056/NEJM199607183350307. [DOI] [PubMed] [Google Scholar]
  15. Szaff M., Høiby N., Flensborg E. W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983 Sep;72(5):651–657. doi: 10.1111/j.1651-2227.1983.tb09789.x. [DOI] [PubMed] [Google Scholar]
  16. Valerius N. H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991 Sep 21;338(8769):725–726. doi: 10.1016/0140-6736(91)91446-2. [DOI] [PubMed] [Google Scholar]
  17. Webb A. K., Govan J. R. Burkholderia cepacia: another twist and a further threat. Thorax. 1998 May;53(5):333–334. doi: 10.1136/thx.53.5.333. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES